Dermatology

Supportive Care

Life-Threatening Dermatologic Toxicity

Sigrid Barklund, BA, MS, and Milan J. Anadkat, MD  / October 15, 2014

A variety of life-threatening dermatologic adverse events may occur in association with cancer drug therapies. Here, we discuss the recognition and management of three types of such toxicities: type I hypersensitivity/anaphylaxis, Stevens-Johnson syndrome/toxic epidermal necrolysis, and drug rash wi...

Skin Cancer

How to Recognize and Manage Intertriginous Eruptions Related to Doxorubicin

Lida Zheng, BS, and Milan J. Anadkat, MD  / July 25, 2014

Intertriginous areas refer to skin folds (such as axillae, inguinal creases, and inframammary creases), which are characterized by increased friction, temperature, and occlusion. Intertriginous drug reactions are an underrecognized side effect associated with pegylated liposomal doxorubicin therapy,...

Supportive Care
Issues in Oncology

Accidental Extravasation of Chemotherapy

Seppo W. Langer, MD PhD  / April 15, 2014

Accidental extravasation of chemotherapy is a rare but feared complication of cancer treatment. Risk factors for extravasation include medication-related factors (such as the vesicant properties of the compound, or the volume, concentration, and duration of the infusion), patient-related factors (su...

Skin Cancer

Melanomas Induced by BRAF Inhibitors 

Ashfaq A. Marghoob, MD, and Sarah Yagerman, BS  / July 10, 2013

Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that re...

Skin Cancer

Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome

Mario E. Lacouture, MD  / December 15, 2012

Multikinase inhibitors (sorafenib [Nexavar], sunitinib [Sutent], pazopanib [Votrient], axitinib [Inlyta], regorafenib [Stivarga]) block various proteins including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). They have been approved by regul...

How to Recognize and Manage Vandetanib-induced Photosensitivity

Mario E. Lacouture, MD  / October 15, 2012

Vandetanib (Caprelsa) is an inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection (RET) tyrosine kinase receptors. It has been approved by regulatory agencies for the treatment of unresectable or metastatic medullary thyroid ca...

Advertisement

Advertisement



Advertisement